![]() Table 1 Baseline clinical characteristics and laboratory data of the study patients. We calculated by two methods, with and without the inclusion of cardiac catheterization variables. Only variables that were statically significant in the univariate analyses were included. Multivariate regression analyses were carried out to determine which variables were independently associated with BNP or NT-proBNP and the relation between log NT-proBNP and log BNP or other clinical characteristics. Univariate linear regression analyses were carried out to evaluate the relationship between BNP or NT-proBNP and clinical characteristics as continuous variables when appropriate. We compared the two groups’ clinical characteristics with the Wilcoxon rank-sum test, but comparison between BNP and NT-proBNP was performed with Mann–Whitney's U-test. All results are expressed as the mean ± S.D, but BNP, NT-proBNP, log BNP, and log NT-proBNP are expressed as the median (25th–75th percentiles), because these were not normally distributed. Plasma levels of BNP and NT-proBNP values were normalized by log 10 transformation. We first calculated the baseline estimated GFR (eGFR) (adjusted for body surface area as ml/min/1.73 m 2) by the three-variable revised equation of the Modification of Diet in Renal Disease equation for GFR in Japanese (eGFR = 194 × serum creatinine −1.094 × age −0.287 × 0.739 ) [ĭata were analyzed using SPSS version 19 (SPSS, IBM, Chicago, IL, USA). Clinical events were analyzed in June, 2010 using clinical records, phone calls, and letters. Of 1083 patients, 1035 (95.6%) were followed up for a mean duration of 51.9 ± 13.5 months. Patients received regular follow-up care in our hospital outpatient ward or another clinic. There were 764 males and 319 females aged between 18 and 90 years (64.9 ± 11.7 years old, mean ± SD). Patients with acute coronary syndrome, acute myocarditis, and the acute phase of heart failure were excluded. This retrospective cohort study enrolled 1083 consecutive patients with cardiovascular disease who underwent elective cardiac catheterization for diagnosis or percutaneous coronary intervention at Nara Medical University Hospital between April 2004 and August 2008. However, for CKD stages 4–5, the AUC for mortality for BNP was 0.713 and that for NT-proBNP was 0.760, while the AUC for the composite end point for BNP was 0.666 and that for NT-proBNP was 0.720. The area under the receiver operating characteristic curve (AUROC) for BNP and NT-proBNP were similar for CKD stages 1–3. During follow-up periods (51.3 ± 0.4 months), 132 patients died and 202 patients reached the composite end point. Baseline plasma BNP and NT-proBNP levels, expressed as log-transformed data, were closely correlated in patients with CKD stages 1–3 ( n = 998) ( r 2 = 0.870, p < 0.001), whereas for CKD stages 4–5 ( n = 85) there was a significant but weaker correlation ( r 2 = 0.209, p < 0.001). The end points were all-cause death and a composite end point of all-cause death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for severe heart failure, and initiation of hemodialysis. This retrospective cohort study evaluated patients with cardiovascular diseases (64.9 ± 11.7 years, mean ± SD). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |